← 返回

异质性γδ T 细胞在癌症治疗中的能力

英文原题:The capability of heterogeneous γδ T cells in cancer treatment.

查看英文原题

The capability of heterogeneous γδ T cells in cancer treatment.

PubMed 2023/11/24(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

γδ T 细胞是 T 淋巴细胞的一个特殊亚群,在肿瘤免疫治疗领域受到了广泛关注。这些细胞处于适应性免疫和固有免疫范式的交汇点,展现出深刻的肿瘤识别能力,提示了新的免疫治疗策略。

值得注意的是,这些细胞能够直接识别并消灭肿瘤细胞,而不依赖于 HLA-抗原呈递。此外,γδ T 细胞能够将肿瘤抗原呈递给 αβ T 细胞,从而增强其抗肿瘤效力。在 γδ T 细胞多样且异质的亚群中,出现了不同的免疫功能,在肿瘤微环境中表现为抗肿瘤或促肿瘤作用。理解并策略性地利用这些异质性 γδ T 细胞群体,对于将其整合到肿瘤特异性免疫治疗模式中至关重要。本综述旨在描述 γδ T 细胞谱系的异质性及其在恶性肿瘤治疗中产生的功能可塑性。本综述致力于阐明 γδ T 细胞谱系固有的复杂异质性、其在对抗恶性肿瘤中随之产生的功能动态、临床试验的最新进展,以及基于 γδ T 细胞的肿瘤干预不断演变的格局,同时探讨阻碍该领域发展的挑战。

展开英文摘要原文

γδ T cells, a specialized subset of T lymphocytes, have garnered significant attention within the realm of cancer immunotherapy. Operating at the nexus between adaptive and innate immunological paradigms, these cells showcase a profound tumor discernment repertoire, hinting at novel immunotherapeutic strategies. Significantly, these cells possess the capability to directly identify and eliminate tumor cells without reliance on HLA-antigen presentation.

Furthermore, γδ T cells have the faculty to present tumor antigens to αβ T cells, amplifying their anti-tumoral efficacy. Within the diverse and heterogeneous subpopulations of γδ T cells, distinct immune functionalities emerge, manifesting either anti-tumor or pro-tumor roles within the tumor microenvironment. Grasping and strategically harnessing these heterogeneous γδ T cell cohorts is pivotal to their integration in tumor-specific immunotherapeutic modalities.

The aim of this review is to describe the heterogeneity of the γδ T cell lineage and the functional plasticity it generates in the treatment of malignant tumors. This review endeavors to elucidate the intricate heterogeneity inherent to the γδ T cell lineage, the consequential functional dynamics in combating malignancies, the latest advancements from clinical trials, and the evolving landscape of γδ T cell-based oncological interventions, while addressing the challenges impeding the field.

论文信息

作者
Yan W、Dunmall LSC、Lemoine NR、Wang Y、Wang Y、Wang P
单位
Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, State Key Laboratory of Esophageal Cancer Prevention & Treatment, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China.China
文献类型
综述 · 非美国政府资助研究
期刊
Frontiers in immunology2023
原文标识
PubMed 38077392 · DOI 10.3389/fimmu.2023.1285801